| Bioactivity | Garenoxacin (BMS284756) Mesylate hydrate is an orally active quinolone antibiotic and has a broad spectrum of activity against a wide array of gram-positive and gram-negative bacteria, anaerobes, and fastidious organisms[1]. |
| Invitro | Garenoxacin (BMS284756) (0-8 days) inhibits mycoplasmas and ureaplasmas with MIC90s ≤0.25 μg/mL against tested strains[1].Garenoxacin (48 h) inhibits S. aureus wild type and mutants with MICs of 0.0128-4.0 μg/mL[2].Garenoxacin inhibits topoisomerase IV and gyrase from S. aureus with IC50s of 1.25 to 2.5 and 1.25 μg/mL, respectively[2].Garenoxacin has a low propensity for selective enrichment of fluoroquinolone-resistant mutants among ciprofloxacin-susceptible isolates of S. aureus[3]. Cell Viability Assay[1] Cell Line: |
| Name | Garenoxacin Mesylate hydrate |
| CAS | 223652-90-2 |
| Formula | C24H26F2N2O8S |
| Molar Mass | 540.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Garenoxacin Mesylate hydrate
CAS: 223652-90-2 F: C24H26F2N2O8S W: 540.53
Garenoxacin (BMS284756) Mesylate hydrate is an orally active quinolone antibiotic and has a broad spectrum of activity a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.